New insights into pulmonary hypertension.
Bryant
B
Furlow
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000235:genetics; D015337:Multicenter Studies as Topic; D020125:Mutation, Missense / Q000235:genetics; D009419:Nerve Tissue Proteins / Q000235:genetics; D024683:Potassium Channels, Tandem Pore Domain / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D009419:Nerve Tissue Proteins; D024683:Potassium Channels, Tandem Pore Domain; D011720:Pyrazoles; D011743:Pyrimidines; C420132:potassium channel subfamily K member 3; C542595:riociguat